Biomarker Levels as A Predictor of Concussion Severity OUTcomes (BlacOut)

Completed

Conditions studied: Concussion, Mild, Neurocognitive Dysfunction

In brief

The overall research aim of this pilot study is to determine if the structural brain protein calpain-cleaved αII-spectrin N-terminal fragment (SNTF) can be used as a blood biomarker to accurately identify patients who will have more severe symptoms and reduced neurocognitive functioning after sustaining a concussion. Concussion is also referred to as mild traumatic brain injury (mTBI) in the literature. Both terms will be used interchangeably throughout this application.

Key facts

Study ID
NCT02992327
Run by
HealthPartners Institute
People needed
100
Starts
2015-08-30
Expected to finish
2018-08-06
Last updated by the study team
2018-09-07

Who can join

Age: 8 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.